# Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants

> **NCT05056246** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 34 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** AMG 133

## Key facts

- **NCT ID:** NCT05056246
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-10
- **Primary completion:** 2022-04-08
- **Final completion:** 2022-04-08
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05056246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05056246, "Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05056246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*